GILD · News · 20260911N

Competition and Market Share Pressure

GILEAD SCIENCES, INC. · 2026-09-11 · Importance 47 · Surprise 60

A federal appeals court upheld a preliminary injunction blocking imports and U.S. sales of foreign-market Gilead-branded HIV medications. The Fourth Circuit found that the foreign versions were materially different from the U.S.-marketed drugs, supporting Gilead’s trademark-violation and unfair-competition claims. The ruling protects the competitive position of Biktarvy in the U.S., although employer health plans continue seeking lower-cost alternatives that could sustain pricing pressure.

Key facts

• Pricing pressures from employer health plans seeking lower-cost alternatives for HIV medications are expected to persist, despite the appeals court ruling. source
• Analysts currently rate GILEAD SCIENCES, INC. with a consensus "Moderate Buy" and a target price of $158.78. source
• Insider and institutional ownership of GILEAD SCIENCES, INC. shares is 83.7%. source